JAMA Psychiatry : GLP-1 Receptor Agonists, Mortality, and CV Outcomes in Mental Illness

From the JAMA Network, this is JAMA Psychiatry Author Interviews, conversations with authors exploring the latest clinical research, reviews, and opinions featured in JAMA Psychiatry.

Hello and welcome to our listeners around the world.

You're listening to the JAMA Psychiatry Author Interview Podcast.

I'm your host and web editor, Dr. John Torres.

Today, we're thrilled to be discussing a new paper just out in JAMA Psychiatry, GLP-1 Receptor Agonists, Mortality and Cardiovascular Outcomes in Serious Mental Illness.

We're about to speak with Professor Roger McIntyre, MD, the Department of Psychiatry and Department of Pharmacology and Toxicology at University of Toronto, as well as the Brain and Cognition Discovery Foundation in Toronto, Ontario, Canada.

People with serious mental illness die on average 10 to 25 years earlier than the general population.

Cardiovascular disease is the single largest driver of that gap, but for decades it has stubbornly persisted.

What if a new class of medications developed for diabetes and obesity, of course, the GLP-1 agonists are always in the news and even covered on prior podcasts here, could actually help? To find out, we're about to speak with the corresponding author of a new study just published in JAMA Psychiatry that examines outcomes of more than 1.5 million people.

So thank you for joining us, Dr. McIntyre.

And to jump in, let's set the stage.

We know that serious mental illness, we'll define it here as major depression, bipolar, and schizophrenia.

People with serious mental illness die earlier than the general population.

Can you walk us through the scale of the mortality gap and why cardiovascular disease is center stage here? John,

From the JAMA Network, this is JAMA Psychiatry Author Interviews, conversations with authors exploring the latest clinical research, reviews, and opinions featured in JAMA Psychiatry.

Hello and welcome to our listeners around the world.

You're listening to the JAMA Psychiatry Author Interview Podcast.

I'm your host and web editor, Dr. John Torres.

Today, we're thrilled to be discussing a new paper just out in JAMA Psychiatry, GLP-1 Receptor Agonists, Mortality and Cardiovascular Outcomes in Serious Mental Illness.

We're about to speak with Professor Roger McIntyre, MD, the Department of Psychiatry and Department of Pharmacology and Toxicology at University of Toronto, as well as the Brain and Cognition Discovery Foundation in Toronto, Ontario, Canada.

People with serious mental illness die on average 10 to 25 years earlier than the general population.

Cardiovascular disease is the single largest driver of that gap, but for decades it has stubbornly persisted.

What if a new class of medications developed for diabetes and obesity, of course, the GLP-1 agonists are always in the news and even covered on prior podcasts here, could actually help? To find out, we're about to speak with the corresponding author of a new study just published in JAMA Psychiatry that examines outcomes of more than 1.5 million people.

So thank you for joining us, Dr. McIntyre.

And to jump in, let's set the stage.

We know that serious mental illness, we'll define it here as major depression, bipolar, and schizophrenia.

People with serious mental illness die earlier than the general population.

Can you walk us through the scale of the mortality gap and why cardiovascular disease is center stage here? John,